कृपया अन्य खोज का प्रयास करें
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Carl Alan Jason Morton Firth | 50 | 2010 | Founder, CEO & Executive Director |
Andrew Howden | 64 | 2016 | Independent Chairman |
Robert E. Hoffman | 57 | 2018 | Independent Non-Executive Director |
Lawrence F. Eichenfield | 64 | 2021 | Chairman of Scientific Advisory Board |
Kathleen M. Metters | 66 | 2021 | Independent Director |
Eric Simpson | - | 2021 | Member of Scientific Advisory Board |
Melinda Jennifer Gooderham | - | 2021 | Member of Scientific Advisory Board |
Neil Graham | 65 | 2021 | Independent Director |
Peter Foley | - | 2021 | Member of Scientific Advisory Board |
Reynold A. Panettieri | - | 2024 | Scientific Advisor |
Ramaswamy Krishnan | - | 2024 | Scientific Advisor |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है